|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/18 | (2006.01) |
| G01N 33/577 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 3339323 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18150424.2 |
| Date of filing the European patent application | 2011-08-09 | |
| (97) | Date of publication of the European application | 2018-06-27 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-13 |
| (46) | Date of publication of the claims translation | 2020-02-10 |
| (30) | Number | Date | Country code |
| 373026 P | 2010-08-12 | US |
| (72) |
Demattos, Ronald Bradley, US
Lu, Jirong, US
Tang, Ying, US
|
| (73) |
ELI LILLY AND COMPANY,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Amiloido beta peptido antikūnai prieš N3Glu ir jų panaudojimas |
| ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-07-23 | 15 | 289.00 EUR |
| 2026-08-09 |